SOURCE: Novo Nordisk A/S

March 02, 2009 08:08 ET

Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - March 2, 2009) - Novo Nordisk A/S - Share repurchase programme

On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 23 February 2009, the following transactions have been made under the programme:

                        Number of shares Average purchase Transaction
                                              price       value, DKK
Accumulated, last
announcement                   1,273,000                  389,599,260
23 February 2009                  75,000           302.55  22,691,250
24 February 2009                  75,000           300.67  22,550,250
25 February 2009                  75,000           296.36  22,227,000
26 February 2009                  75,000           298.27  22,370,250
27 February 2009                  87,000           287.22  24,988,140
Accumulated under
the programme                  1,660,000                  504,426,150

With the transactions stated above, Novo Nordisk owns a total of 26,464,435 treasury shares, corresponding to 4.2% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Further information:

Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919

                       Kasper Roseeuw Poulsen
                       Tel: 4442 4471

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937

Company Announcement no. 12 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.

Contact Information